Is there any medical insurance for Moboxetinib Succinate Capsules?

Moboxetinib succinate capsules have been launched in China, but have not yet been included in my country's medical insurance system, which means that patients need to pay the full cost of the drug. In China, the latest price of 40mg*112 capsules of moboxetinib capsules is around 40,000 to 50,000 yuan, which is a heavy financial burden for many patients. Therefore, some patients may consider looking for more reasonably priced generic or original drugs from overseas markets such as India, Bangladesh or Laos. However, no matter which route you choose, you need to ensure that the medicine comes from a reliable source to ensure that the treatment is safe and effective.

Mobosetinib, chemically known as Mobosetinib Succinate Capsules, is a new generation of powerful oral small molecule tyrosine kinase inhibitors (TKIs). This drug is specifically designed to selectively target EGFR exon 20 insertion mutations, providing a new treatment option for patients with non-small cell lung cancer (NSCLC).

The clinical trial data for mobotinib are excellent. In a phase 1/2 trial, 114 patients with platinum-treated EGF were enrolled. Patients with Rexon20insertion mutationsNSCLC were treated with mobotinib. The results showed that the overall response rate was 35% as assessed by the investigators and 28% as assessed by the independent review committee. The median progression-free survival of patients was 7.3 months, and the median overall survival was 24 months.

Mobotinib, as a targeted drug that specifically targets EGFR exon 20 insertion mutations, provides a new treatment option for patients with non-small cell lung cancer.